Any changes Robert F. Kennedy Jr. wants to make will come up against a pharmaceutical industry that pays much of the U.S. Food and Drug Administration's bills.

Staff turnover is typical when a new administration comes in, and a significant number of FDA employees similarly considered leaving before President-elect Donald Trump’s first term in office, said one former and one current official.